| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/23/2001 | WO2001060357A1 New use |
| 08/23/2001 | WO2001060355A1 Modulation of bone formation |
| 08/23/2001 | WO2001060352A1 Use of alpha 1a adrenoceptor agonists with alpha 1b and alpha 1d antagonism for the treatment of stress urinary incontinence |
| 08/23/2001 | WO2001060350A2 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| 08/23/2001 | WO2001060349A2 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 08/23/2001 | WO2001060348A2 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 08/23/2001 | WO2001060345A2 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator |
| 08/23/2001 | WO2001060325A1 Pharmaceutical composition |
| 08/23/2001 | WO2001060315A2 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 08/23/2001 | WO2001060278A2 Oral therapeutic delivery appliance |
| 08/23/2001 | WO2001060179A1 Improvements in or relating to solubilisation of flavonols |
| 08/23/2001 | WO2001060174A2 Weight loss induced by reduction in neuropeptide y level |
| 08/23/2001 | WO2001025793A3 Diagnosis of coeliac disease using a gliadin epitope |
| 08/23/2001 | WO2001024807A3 Method for calming human beings using personal care compositions |
| 08/23/2001 | WO2001013903A3 Treatment of restless leg syndrome with a combination of clonidine and opioid |
| 08/23/2001 | WO2001010387A3 Antiviral therapy use of P-glycoprotein modulators |
| 08/23/2001 | WO2001007611A3 Novel polynucleotides and method for the use thereof |
| 08/23/2001 | WO2000078954A3 Human transcriptional regulator proteins |
| 08/23/2001 | WO2000074634A3 Methods and compositions for modulating cell proliferation and cell death |
| 08/23/2001 | WO2000067738A3 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders |
| 08/23/2001 | WO2000061126A3 Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators |
| 08/23/2001 | WO2000044364A3 P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
| 08/23/2001 | WO2000023066A3 Irrigation solution and method for inhibition of pain and inflammation |
| 08/23/2001 | WO2000021514A3 Method and composition for treating and preventing tuberculosis |
| 08/23/2001 | WO2000006738A3 NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 08/23/2001 | US20010016731 Methods and apparatus for accelerated orthokeratology |
| 08/23/2001 | US20010016644 Protein of given molecular weight and given N-terminal amino acid sequence |
| 08/23/2001 | US20010016604 Mixing a cosmetic or pharmaceutical agent in a vehicle for topical administration to the skin of humans or animals with hydroxycarboxylic acid and related ketocarboxylic acid and ester, lactone or salt forms |
| 08/23/2001 | US20010016600 Method of treating cancer using dithiocarbamate derivatives |
| 08/23/2001 | US20010016586 Use of organic compounds |
| 08/23/2001 | US20010016583 Therapeutic application of pro-apoptotic benzodiazepines |
| 08/23/2001 | US20010016580 In combination with nicotinic acid, picolinic acid or both useful for dietary supplementation, lowering blood glucose or serum lipid levels and increasing body mass; enteric-coated tablets, capsules or microbeads |
| 08/23/2001 | US20010016570 Bone disorders |
| 08/23/2001 | US20010016338 DNA molecule encoding a variant alpha2B-adrenoceptor protein, and uses thereof |
| 08/23/2001 | US20010016336 Genetic engineered polypeptide |
| 08/23/2001 | US20010016332 Genetic engineering |
| 08/23/2001 | US20010016329 Methods and compositions for overcoming resistance to biologic and chemotherapy |
| 08/23/2001 | US20010016319 Cloning of a novel G-protein coupled 7TM Receptor |
| 08/23/2001 | US20010016194 Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same |
| 08/23/2001 | DE10007203A1 Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist |
| 08/23/2001 | DE10006309A1 Verfahren zur Identifizierung von Substanzen, die die Aktivität von hyperpolarisationsaktivierten Kationen-kanälen modulieren A method for identifying substances that modulate the activity of hyperpolarization-activated cation channels, |
| 08/23/2001 | DE10002820A1 Aminopeptidasen-Inhibitor Aminopeptidase inhibitor |
| 08/23/2001 | CA2400588A1 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 08/23/2001 | CA2400374A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | CA2400355A1 Pancreatic islet cell growth factors |
| 08/23/2001 | CA2400274A1 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 08/23/2001 | CA2400256A1 Compositions useful for regulating parkin gene activity |
| 08/23/2001 | CA2400209A1 Oral therapeutic delivery appliance |
| 08/23/2001 | CA2400206A1 Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| 08/23/2001 | CA2400197A1 Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| 08/23/2001 | CA2400178A1 Nail lacquer pharmaceutical composition |
| 08/23/2001 | CA2400136A1 Weight loss induced by reduction in neuropeptide y level |
| 08/23/2001 | CA2400101A1 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 08/23/2001 | CA2400034A1 Human kinases |
| 08/23/2001 | CA2400021A1 Aryloxyacetic acids for diabetes and lipid disorders |
| 08/23/2001 | CA2399810A1 Modulation of bone formation |
| 08/23/2001 | CA2399219A1 Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |
| 08/23/2001 | CA2398861A1 Gene disruption methodologies for drug target discovery |
| 08/23/2001 | CA2398691A1 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 08/23/2001 | CA2398628A1 5ht3 receptors of nematodes, polynucleotide molecules encoding same, andantagonists thereof |
| 08/23/2001 | CA2398603A1 Fibroblast growth factor-23 molecules and uses thereof |
| 08/23/2001 | CA2397768A1 Use of alpha 1a adrenoceptor agonists with alpha 1b and alpha 1d antagonism for the treatment of stress urinary incontinence |
| 08/23/2001 | CA2397458A1 Improvements in or relating to solubilisation of flavonols |
| 08/23/2001 | CA2396793A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| 08/23/2001 | CA2395473A1 Microcompetiton and human disease |
| 08/23/2001 | CA2337616A1 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/22/2001 | EP1126028A1 Novel g protein-coupled receptor proteins, dnas thereof and ligands to the same |
| 08/22/2001 | EP1125936A2 Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases |
| 08/22/2001 | EP1125585A1 Remedies for immunological diseases |
| 08/22/2001 | EP1125582A2 Use of estrogen agonists / antagonists for the treatment of sexual dysfunction |
| 08/22/2001 | EP1125580A2 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 08/22/2001 | EP1125579A2 Uses of agrp-melanocortin receptor binding modulating compounds |
| 08/22/2001 | EP1124959A1 Cell surface molecule-induced macrophage activation |
| 08/22/2001 | EP1124953A2 New transcription factor of mhc class ii genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| 08/22/2001 | EP1124951A2 Human sorting nexins |
| 08/22/2001 | EP1124950A2 p53 ANTISENSE AGENT AND METHOD |
| 08/22/2001 | EP1124855A2 Compositions and methods for treating polycystic kidney disease |
| 08/22/2001 | EP1124848A2 Transmembrane 4 proteins |
| 08/22/2001 | EP1124841A1 Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them |
| 08/22/2001 | EP1124592A2 Textured and porous silicone rubber |
| 08/22/2001 | EP1124580A1 Enhanced radiation therapy |
| 08/22/2001 | EP1124572A2 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 08/22/2001 | EP1124571A1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia |
| 08/22/2001 | EP1124567A2 Buffered compositions for dialysis |
| 08/22/2001 | EP1124563A2 Methods and compositions for the prevention of tolerance to medications |
| 08/22/2001 | EP1124562A1 Combination therapy to treat hepatitis b virus |
| 08/22/2001 | EP1124560A1 Use of antifungal agents for treating scleroses |
| 08/22/2001 | EP1124559A1 Compositions for the treatment and prevention of neurological and pathopsychological diseases |
| 08/22/2001 | EP1124555A1 Method of treating neurodegenerative diseases |
| 08/22/2001 | EP1124553A1 New use of glutamate antagonists for the treatment of cancer |
| 08/22/2001 | EP1124548A2 Compositions for the treatment and prevention of cardiovascular diseases |
| 08/22/2001 | EP1124547A1 Pharmaceutical combination of mildronate and enalapril |
| 08/22/2001 | EP1124535A1 Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap |
| 08/22/2001 | EP1124418A1 Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
| 08/22/2001 | EP0833611B1 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof |
| 08/22/2001 | EP0809516B1 Medicinal combination useful for in vivo exogenic transfection and expression |
| 08/22/2001 | EP0696208B1 Oral drug delivery compositions |
| 08/22/2001 | EP0673255B1 Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof |
| 08/22/2001 | CN1309720A Virulence-associated nucleic acid sequences and uses thereof |
| 08/22/2001 | CN1309659A Phosphorous organic compounds and their use |